Serum transforming growth factor β and leucine-rich α-2-glycoprotein 1 as potential biomarkers for diagnosis of uterine leiomyomas

Kamalipooya, Samaneh; Zarezadeh, Reza; Latifi, Zeinab; Nouri, Mohammad; Fattahi, Amir; Saberi, Zahra

doi:10.1016/j.jogoh.2020.102037

Cited by 7 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our previous findings, we discovered that the levels of TGF-β and leucine-rich α-2-glycoprotein 1 (LRG1) were significantly higher in patients with leiomyomas. 19 Therefore, it can be hypothesized that one of the mechanisms by which VitD suppresses the development of leiomyomas is through the reduction of LRG1, thus modulating LRG1-dependent TGF-β signaling. This potential signaling has been confirmed by Lu et al, 39 who demonstrated that LRG1 is one of the genes regulated by VitD.…”

Section: Discussionmentioning

confidence: 99%

“…It is important to note that some of the samples used in this study were taken from a previously published study. 19 Patients were diagnosed with leiomyomas if they had at least one fibroid lump with a mean diameter of ≥5 mm, as diagnosed by thorough transvaginal ultrasonography. This diagnosis was later confirmed through histopathological examination of discarded fibroids.…”

Section: Methodsmentioning

confidence: 99%

“…These women underwent trans‐vaginal ultrasonography to confirm the absence of any uterine leiomyoma. It is important to note that some of the samples used in this study were taken from a previously published study 19 . Patients were diagnosed with leiomyomas if they had at least one fibroid lump with a mean diameter of ≥5 mm, as diagnosed by thorough trans‐vaginal ultrasonography.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Vitamin D and its binding protein in patients with leiomyomas

Latifi,

Oghbaei,

Salemi

et al. 2024

J of Obstet and Gynaecol

Self Cite

View full text Add to dashboard Cite

AimThis study examined the levels of VitD, VitD binding protein (DBP), and free VitD in leiomyomas patients and their association with the quantity, dimensions, and site of fibroid growths. Additionally, we evaluated the potentiality of employing these factors as a biomarker tool for the diagnosis and assessment of uterine fibroid progression.MethodsThis study involved the participation of 55 women with leiomyomas and 50 healthy women. We utilized commercial ELISA kits to measure the levels of total VitD and DBP in their serum. Additionally, we calculated the levels of free VitD and the ratio of VitD to DBP. Moreover, we determined the number, size, and location of the leiomyomas in the patients.ResultsThere were no significant differences in the levels of total VitD between the groups. However, patients had significantly lower levels of free VitD and higher levels of DBP compared to the control group. The size of the largest leiomyomas showed a negative relationship with free VitD and a positive relationship with DBP. Receiver operating characteristic analyses, showed that the cut‐off value for free VitD was 4.47 pg/mL, with a sensitivity of 75.6% and a specificity of 74.4%. The cut‐off value for DBP was 256.2 μg/mL, with a sensitivity of 86% and a specificity of 70.3%.ConclusionsFree VitD and DBP potentially contribute to the development of leiomyomas and are linked to the size of these tumors. The measurement of serum levels of these factors could serve as additional biomarkers for the diagnosis of leiomyomas.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Vitamin D and its binding protein in patients with leiomyomas

Latifi,

Oghbaei,

Salemi

et al. 2024

J of Obstet and Gynaecol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recent advances in the interpretation of the molecular mechanism of LRG1 in tumor indicated that long noncoding RNA taurine upregulated one mediated endothelial angiogenesis through the LRG1/TGF-β pathway (Fan et al, 2019), which could predict clinical outcomes after transarterial chemoembolization (Peng et al, 2020). Elevated serum levels of TGF-β1 and LRG1 were associated with morbidity and severity of uterine leiomyoma (Kamalipooya et al, 2021). Other findings imply that LRG1 was correlated with the diagnosis of squamous cell carcinoma of the head and neck (Wang et al, 2017a), tongue carcinoma (Hao L. J. et al, 2016), oral cancer (Chang et al, 2019), retinoblastoma (Luan et al, 2021), thyroid carcinoma (Ban et al, 2019), hepatocellular carcinoma (Yu et al, 2017), lung adenocarcinoma (Pu et al, 2020), and diffuse large B-cell lymphoma .…”

Section: Part Four: Lrg1 Involved In Tumor Diseasesmentioning

confidence: 99%

Research Progress on Leucine-Rich Alpha-2 Glycoprotein 1: A Review

Zou

Chen

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Leucine-rich alpha⁃2 glycoprotein 1 (LRG1) is an important member of the leucine-rich repetitive sequence protein family. LRG1 was mainly involved in normal physiological activities of the nervous system, such as synapse formation, synapse growth, the development of nerve processes, neurotransmitter transfer and release, and cell adhesion molecules or ligand-binding proteins. Also, LRG1 affected the development of respiratory diseases, hematological diseases, endocrine diseases, tumor diseases, eye diseases, cardiovascular diseases, rheumatic immune diseases, infectious diseases, etc. LRG1 was a newly discovered important upstream signaling molecule of transforming growth factor⁃β (TGF⁃β) that affected various pathological processes through the TGF⁃β signaling pathway. However, research on LRG1 and its involvement in the occurrence and development of diseases was still in its infancy and the current studies were mainly focused on proteomic detection and basic animal experimental reports. We could reasonably predict that LRG1 might act as a new direction and strategy for the treatment of many diseases.

show abstract

“…However, only some of these show significant differences in healthy and fibroid patients and could be used in clinical practice. Potential serum biomarkers for uLM include proteins involved in oxidative stress, such as vitamin D3 or AOPP [149][150][151][152], inflammatory processes, such as YKL-40 [153] and TRADD [154], and angiogenesis, such as TGF-β and LRG1 [155].…”

Section: Detection-putative Biomarkersmentioning

confidence: 99%

Molecular and Cellular Insights into the Development of Uterine Fibroids

Machado-Lopez

Simón

Mas

2021

IJMS

View full text Add to dashboard Cite

Uterine leiomyomas represent the most common benign gynecologic tumor. These hormone-dependent smooth-muscle formations occur with an estimated prevalence of ~70% among women of reproductive age and cause symptoms including pain, abnormal uterine bleeding, infertility, and recurrent abortion. Despite the prevalence and public health impact of uterine leiomyomas, available treatments remain limited. Among the potential causes of leiomyomas, early hormonal exposure during periods of development may result in developmental reprogramming via epigenetic changes that persist in adulthood, leading to disease onset or progression. Recent developments in unbiased high-throughput sequencing technology enable powerful approaches to detect driver mutations, yielding new insights into the genomic instability of leiomyomas. Current data also suggest that each leiomyoma originates from the clonal expansion of a single transformed somatic stem cell of the myometrium. In this review, we propose an integrated cellular and molecular view of the origins of leiomyomas, as well as paradigm-shifting studies that will lead to better understanding and the future development of non-surgical treatments for these highly frequent tumors.

show abstract

Serum transforming growth factor β and leucine-rich α-2-glycoprotein 1 as potential biomarkers for diagnosis of uterine leiomyomas

Cited by 7 publications

References 27 publications

Vitamin D and its binding protein in patients with leiomyomas

Vitamin D and its binding protein in patients with leiomyomas

Research Progress on Leucine-Rich Alpha-2 Glycoprotein 1: A Review

Molecular and Cellular Insights into the Development of Uterine Fibroids

Contact Info

Product

Resources

About